The effect of the Russian combined vector vaccine against the novel coronavirus infection caused by SARS-CoV-2 on ovarian reserve and menstrual function in reproductive-aged women


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Relevance: Despite the widespread use of COVID-19 vaccination worldwide, the number of studies on the impact of various types of vaccines on women’s reproductive health is limited in the scientific literature. The preliminary results of the study on the negative effect of vaccination with the Russian Gam-COVID-Vac vaccine on the ovarian reserve and the level of antiphospholipid antibodies in reproductive-aged women were first published in 2021. Objective: To evaluate the effect of the Russian combined vector vaccine against the novel coronavirus infection caused by SARS-CoV-2 on the parameters of ovarian reserve and menstrual function in reproductive-aged women. Materials and methods: A prospective interventional study included 220 women vaccinated with a combined vector vaccine Gam-COVID-Vac for the prevention of a novel coronavirus infection caused by SARS-CoV-2. The inclusion criteria were age from 18 to 45, preserved menstrual function, no history of COVID-19, negative PCR test result for SARS-CoV-2 and negative SARS-CoV-2 IgG antibody test before vaccination, no pregnancy, and no history of serious illnesses. The patients were examined twice: immediately before vaccination and 90 days after the first dose was injected. Antral follicle count was determined during the ultrasound examination of the pelvic organs. Serum levels of AMH, FSH, estradiol on the 2nd-5th day of the menstrual cycle, as well as IgG antibodies to SARS- CoV-2 were measured using enzyme immunoassay. Results: The efficacy and safety of the Russian combined vector vaccine against COVID-19 was high. The humoral immune response (specific IgG to SARS-CoV-2) was detected in 98.6% of vaccinated patients. There were no cases of severe side effects after vaccination. There were no significant changes in the hormone levels, antral follicle counts and menstrual function before and after vaccination; women of advanced reproductive age (≥37years) did not show considerable changes either. Conclusion: The results of the study indicate that vaccination with a combined vector vaccine Gam-COVID-Vac against a novel coronavirus infection caused by SARS- CoV-2 is effective and safe; it does not have a negative effect on ovarian reserve and menstrual function in reproductive-aged women.

Full Text

Restricted Access

About the authors

Nataliya V. Dolgushina

Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: _dolgushina@oparina4.ru
MD, PhD, Professor, Deputy Director - Chief of the Department for Scientific Projects Organization

Alina A. Dovgan

Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: lina.dovgan@gmail.com
MD, Postgraduate Student, Prof. BV. Leonov Department of Assistive Technologies in Infertility Treatment

Yuliya S. Drapkina

Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: yu_drapkina@oparina4.ru
MD, PhD, Prof. BV. Leonov Department of Assistive Technologies in Infertility Treatment

Tatyana Yu. Ivanets

Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: t_ivanets@oparina4.ru
MD, PhD, Head of the Clinical Diagnostic Laboratory

Valentina V. Vtorushina

Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: vtorushina@inbox.ru
PhD, Doctor of Clinical Laboratory Diagnostics

Alexander I. Gus

Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

MD, PhD, Professor, Chief Researcher at the Department of Ultrasound and Functional Diagnostics

Gennady T. Sukhikh

Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: g_sukhikh@oparina4.ru
Dr. Med. Sci., Professor, Academician of the RAS, Director

References

  1. Logunov D.Y., Dolzhikova I., Shcheblyakov D., Tukhvatulin A.I., Zubkova O.V., Dzharullaeva A.S. et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021; 397(10275): 671-81. https://dx.doi.org/10.1016/S0140-6736(21)00234-8.
  2. Orvieto R., Noach-Hirsh M., Segev-Zahav A., Haas J., Nahum R., Aizer A. Does mRNA SARS-CoV-2 vaccine influence patients’ performance during IVF-ET cycle? Reprod. Biol. Endocrinol. 2021; 19(1): 69. https://dx.doi.org/10.1186/s12958-021-00757-6.
  3. Bentov Y., Beharier O., Moav-Zafrir A., Kabessa M., Godin M., Greenfield C.S. et al. Ovarian follicular function is not altered by SARS-CoV-2 infection or BNT162b2 mRNA COVID-19 vaccination. Hum. Reprod. 2021; 36(9): 2506 13. https://dx.doi.org/10.1093/humrep/deab182
  4. Lifshitz D., Haas J., Lebovitz O., Raviv G., Orvieto R., Aizer A. Does mRNA SARS-CoV-2 vaccine detrimentally affect male fertility, as reflected by semen analysis? Reprod. Biomed. Online. 2022; 44(1): 145-9. https://dx.doi.org/10.1016/j.rbmo.2021.09.021.
  5. Gonzalez D.C., Nassau D.E., Khodamoradi K., Ibrahim E., Blachman-Braun R., Ory J. et al. Sperm Parameters Before and After COVID-19 mRNA Vaccination. JAMA. 2021; 326(3): 273-4. https://dx.doi.org/10.1001/jama.2021.9976.
  6. Mohr-Sasson A., Haas J., Abuhasira S., Sivan M., Doitch Amdurski H., Dadon T. et al. The effect of Covid-19 mRNA vaccine on serum anti-Mullerian hormone levels. Hum. Reprod. 2022; 37(3): 534-41. https://dx.doi.org/10.1093/humrep/deab282.
  7. Драпкина Ю.С., Долгушина Н.В., Шатылко Т.В., Николаева М.А., Менжинская И.В., Иванец Т.Ю., Кречетова Л.В., Красный А.М., Гамидов С.И., Байрамова ГР, Сухих Г.Т. Вакцина Гам-КОВИД-Вак (Спутник V) не оказывает негативного влияния на сперматогенез у мужчин. Акушерство и гинекология. 2021; 7: 88-94. [Drapkina Yu.S., Dolgushina N.V., Shatylko T.V., Nikolaeva M.A., Menzhinskaya I.V., Ivanets T.Yu., Krechetova L.V., Krasnyi A.M., Gamidov S.I., Bairamova G.R., Sukhikh G.T. Gam-COVID-Vac (Sputnik V) vaccine has no adverse effect on spermatogenesis in men. Akusherstvo i Ginekologiya/ Obstetrics and Gynecology. 2021; 7: 88-94 (in Russian)]. https://dx.doi.org/10.18565/aig.202L7.88-94.
  8. Долгушина Н.В., Драпкина Ю.С., Кречетова Л.В., Иванец Т.Ю., Менжинская И.В., Гус А.И., Байрамова Г.Р., Сухих Г.Т. Вакцина Гам-КОВИД-Вак (Спутник V) не оказывает негативного влияния на овариальный резерв у женщин репродуктивного возраста. Акушерство и гинекология. 2021; 7: 81-6. https://dx.doi.org/10.18565/aig.2021.7.81-86.
  9. Guimaraes L.E., Baker B., Perricone C., Shoenfeld Y. Vaccines, adjuvants and autoimmunity. Pharmacol. Res. 2015; 100(January): 190-209. https://dx.doi.org/10.1016/j.phrs.2015.08.003.
  10. Shoenfeld Y., Agmon-Levin N. “ASIA” - autoimmune/inflammatory syndrome induced by adjuvants. J. Autoimmun. 2011; 36(1): 4-8. https://dx.doi.org/10.1016/j.jaut.2010.07.003.
  11. Watad A., Bragazzi N.L., McGonagle D., Adawi M., Bridgewood C., Damiani G. et al. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) demonstrates distinct autoimmune and autoinflammatory disease associations according to the adjuvant subtype: Insights from an analysis of 500 cases. Clin. Immunol. 2019; 203(March): 1-8. https://dx.doi.org/10.1016/j.clim.2019.03.007.
  12. Carp H.J.A., Selmi C., Shoenfeld Y. The autoimmune bases of infertility and pregnancy loss. J. Autoimmun. 2012; 38(2-3): J266-74. https://dx.doi.org/10.1016/j.jaut.2011.11.016.
  13. Cruz-Tapias P., Blank M., Anaya J.M., Shoenfeld Y. Infections and vaccines in the etiology of antiphospholipid syndrome. Curr. Opin. Rheumatol. 2012; 24(4): 389-93. https://dx.doi.org/10.1097/BOR.0b013e32835448b8.
  14. Zivkovic I., Stojanovic M., Petrusic V., Inic-Kanada A., Dimitrijevic L. Induction of APS after TTd hyper-mmunization has a Different Outcome in BALB/c and C57BL/6 Mice. Am. J. Reprod. Immunol. 2011; 65(5): 492-502. https://dx.doi.org/10.1111/j.1600-0897.2010.00922.x.
  15. Zhang H., Penninger J.M., Li Y., Zhong N., Slutsky A.S. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020; 46(4): 586-90. https://dx.doi.org/10.1007/s00134-020-05985-9.
  16. Vaz-Silva J., Carneiro M.M., Ferreira M.C., Pinheiro S.V.B., Silva D.A., Silva A.L. et al. The vasoactive peptide angiotensin-(1-7), its receptor mas and the angiotensin-converting enzyme type 2 are expressed in the human endometrium. Reprod. Sci. 2009; 16(3): 247-56. https://dx.doi.org/10.1177/1933719108327593.
  17. Valdes G., Neves L.A.A., Anton L., Corthorn J., Chacon C., Germain A.M. et al. Distribution of angiotensin-(1-7) and ACE2 in human placentas of normal and pathological pregnancies. Placenta. 2006; 27(2-3): 200-7. https://dx.doi.org/10.1016/j.placenta.2005.02.015.
  18. Ding T., Wang T., Zhang J., Cui P., Chen Z., Zhou S. et al. Analysis of ovarian injury associated with COVID-19 disease in reproductive-aged women in Wuhan, China: An observational study. Front. Med. 2021; 8: 635255. https://dx.doi.org/10.3389/fmed.2021.635255.
  19. Долгушин Г.О., Романов А.Ю. Влияние SARS-CoV-2 на репродукцию человека. Акушерство и гинекология. 2020; 11: 6-12. [Dolgushin G.O., Romanov A.Yu. Impact of SARS-CoV-2 on human reproduction. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2020; 11: 6-12 (in Russian)]. https://dx.doi.org/10.18565/aig.2020.11.6-12.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies